High-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT) improves survival in myeloma (MM). The role of induction therapy on outcomes of ASCT in MM has not been systematically studied. Nonmyelosuppressive (NMS) steroid-based induction can be used in MM, with the potential of reducing neutropenias and other toxic effects prior to ASCT. NMS induction however could be associated with poorer outcomes if disease control or stem cell collection were inadequate. We studied outcomes of 136 MM patients who underwent HDC and ASCT as part of their initial therapy between March 1998 and December 2000. Of these, 46 received HDC and ASCT without any exposure to myelosuppressive agents, 39 received myelosuppressive therapy for disease control and/or stem cell collection, and 51 received alkylating agent-based initial treatment. We compared OS and EFS rates, stem cell collectability, and contamination of the grafts with monoclonal plasma cells. After a median of 33 months, response rates, EFS and OS rates were comparable in the three groups of patients. Adequacy of stem cell collection and plasma cell contamination were similar. Our data support the hypothesis that NMS induction for patients with MM is safe and effective and does not compromise the results of HDC.
plant; nonmyelosuppressive induction; dexamethasone High-dose chemotherapy (HDC) with autologous stem cell transplant (ASCT), has recently been shown to increase rates of overall response, survival, and event-free survival when administered as part of the initial therapy to appropriate patients with multiple myeloma. 1, 2 Prior to HDC patients receive some form of induction therapy to control the disease and reduce tumor burden. 3, 4 The effects of the type of induction therapy on transplant outcomes in myeloma have not been systematically studied. In chronic myelogenous leukemia prior exposure to busulfan has a negative impact on outcomes of allografted patients. 5 In myeloma, extensive exposure to melphalanbased therapies damages stem cells and hampers the ability to collect adequate numbers of stem cells; and affects platelet recovery after transplant. 6 Thus for most patients considered potential candidates for autologous transplantation induction therapy usually consists of high-dose steroids in combination with an anthracycline and a vinca alkaloid (VAD or VAD-like regimens).
The optimal induction therapy for myeloma patients who will eventually undergo ASCT is not known. Highdose dexamethasone therapy represents the single most active component of most induction regimens. 7, 8 Nonmyelosuppressive (NMS) induction regimens combining dexamethasone with thalidomide have recently been shown to be effective in the primary treatment of multiple myeloma, with results comparable to those obtained with more traditional induction chemotherapy regimens. 9, 10 Theoretical benefits of a dexamethasone-based NMS induction regimen would include the following:
(1) Decreased toxicity of induction therapy (2) Decreased exposure of stem cells to cytotoxic chemotherapy (3) Less disruption of quality of life (4) Increase in the number of patients undergoing autografts However, NMS could theoretically worsen transplant outcomes if it resulted in inferior disease control, higher relapse rates, or collection of inferior quality stem cells. To study the potential effects of a NMS induction therapy in patients with multiple myeloma who underwent an autologous transplant in a single institution a retrospective analysis was performed focusing on the effects of NMS induction on quality of stem cell collection and post transplant outcomes. This paper summarizes the results of this analysis.
Patients and methods

Eligibility criteria
The Department of Blood and Marrow Transplantation maintains a complete database of all patients with multiple myeloma who have undergone ASCT at the University of Texas MD Anderson Cancer Center. For this analysis, we included only patients who underwent an ASCT between March 1998 and December 2000 and had the ASCT done within 12 months of initiation of primary therapy and were transplanted for consolidation of a first remission or for lack of response to induction therapy (ie primary refractory disease). We identified 136 patients who fulfilled the inclusion criteria. All patients signed written informed consent for the transplant therapy, and were treated under institutional review board (IRB) approved protocols. The retrospective analysis was performed with written approval of the institutional review board.
Patients and disease characteristics
Patient characteristics are summarized in Table 1 . In brief, median patient age was 53 years (range 30-69), and median time from diagnosis to transplant was 7 months (range 2.7-30.8) At the time of transplant, 100 patients were in first remission while 36 patients had not achieved at least partial remission (ie primary refractory disease).
In all, 85 patients received pulses of dexamethasone (40 mg daily) on days 1-4, 9-12, and 17-21 for at least two cycles as first treatment without any exposure to myelosuppressive treatment. Of these 85, 46 patients (group A) proceeded to peripheral blood stem cell collection with granulocyte colony-stimulating factor (G-CSF) mobilization and received HDC without any previous exposure to myelosuppressive agents. The rest 39 (group B) received myelosuppressive chemotherapy (most frequently a combination of cyclophosphamide, doxorubicin, vincristine, and pulse dexamethasone) prior to ASCT for control of their disease and/or stem cell mobilization.
11 Group C consisted of 51 patients who received myelosuppressive induction chemotherapy either with alkylating agents or anthracyclines in combination with steroids as first-line induction therapy.
Stem cell collection
The regimen used to mobilize stem cells and number of pheresis days needed for adequate stem cell collection (44 Â 10 6 CD34 þ cells/kg) was recorded for every patient. Samples from the pheresis products were examined by flow cytometry. Graft contamination with monoclonal plasma cell (MPC) populations, was identified by measuring the percentages of cytoplasmic kappa and lambda light-chain proteins and the expression of CD38 in the lymphocytes collected and are summarized in Table 2 . DOTMP (a bone-seeking radioisotope) with or without total body irradiation; 13 31 patients received high-dose thiotepa, busulfan, and cyclophosphamide (TBC) as described elsewhere; 14 and 13 patients received a combination of topotecan, melphalan, and cyclophosphamide. 15 Patients from group A were more likely to have received a holmium-DOTMP preparative regimen, whereas patients from groups B and C were more likely to have received HDM or TBC.
All patients received standard post ASCT supportive care which included growth factors, blood transfusions, prophylactic, or therapeutic antibiotics. Post transplant maintenance therapy varied and specific data was not available for all patients included in this analysis.
Outcomes
Engraftment was defined as achievement of an absolute neutrophil count of greater than 0.5 Â 10 9 /l for 3 consecutive days and platelet engraftment defined as platelet counts greater than 50 Â 10 9 /l, without transfusions. Responses were defined using the EBMT/IBMTR consensus criteria which require disappearance of the monoclonal protein, by immunofixation and a normal bone marrow examination. For nonsecretory myelomas, 450% reduction of bone marrow plasma cells or o5% bone marrow plasma cells were considered for partial or complete responses, respectively. 16 Survival-and event-free survival durations were calculated from the day of ASCT using the methods of Kaplan and Meier. 17 
Statistical methods
Patient characteristics were compared among treatment groups by the w 2 test for categorical variables and by the Kruskal-Wallis test for variables measured on a continuous scale. The two-sided log-rank test was used to test the association between variables and EFS. Multivariate analysis was done using the Cox proportional hazards regression model to determine the association of treatment with PFS after adjusting for the roles of other factors. All P values presented are two-sided. Statistical analyses were carried out using SAS 8.2 and Splus 6 software.
Results
Patient characteristics
Groups were comparable in most disease characteristics with the exception that patients in group A had lower b 2 -microglobulin levels at diagnosis and tended to have lower stage disease.
Stem cell collection data
Of the 136 patients in the study, 135 received mobilized peripheral blood stem cells and one underwent bone marrow harvest. Stem cells were mobilized with G-CSF alone in 102 patients and with Hyper-CVAD chemotherapy in 33. 11 Number of pheresis days, percentage of CD34 þ cells collected in the pheresis products, and incidence of MPC contamination of the grafts is summarized in Table 2 .
Patients are grouped according to mobilization treatment (G-CSF alone vs chemotherapy) and according to our initial groups A, B, and C. Only two patients with refractory disease did not mobilize adequate stem cells with G-CSF; and eventually had enough stem cells collected either after chemo-mobilization or bone marrow NMS induction prior to ASCT in myeloma A Anagnostopoulos et al harvest. All other patients achieved adequate stem cell collection after 1-6 sessions of leukapheresis.
Engraftment
All patients recovered neutrophil counts greater than 0.5 Â 10 9 /l after a median of 10 days (range 8-27). Five patients did not achieve platelet counts of at least 50 Â 10 9 /l, three in group C and one each in groups A and B. All others engrafted platelets after a median of 14 days after transplant. Time to engraftment was similar in the three study groups.
Transplant outcomes
In all, 74% of the patients (n ¼ 101) responded to the ASCT with either CR (n ¼ 36, 26%) or PR (n ¼ 65, 48%). CR and PR rates were 39 and 46% for group A, 16 and 45% for group B, and 27 and 52% for group C (P ¼ not significant). After a median follow-up interval of 24 months (range 3-49), 111 patients (82%) were still alive. Of the 25 patients who died, eight (6%) died for reasons other than progression, three (2%) of them within 100 days after transplant The three early deaths were caused by CNS hemorrhage, PCP pneumonia, and multiorgan failure. The other five nondisease-related deaths were caused by cerebrovascular events (n ¼ 3) and infections (n ¼ 2). Overall, 64 patients (44%) have experienced disease progression. Median EFS for all patients was 24 months (95% CI: 20, 30 months).
Association between patient and treatment characteristics and EFS Table 3 provides EFS information according to patient characteristics. Results show that lower stage at diagnosis and b 2 -microglobulin level at the time of ASCT were associated with statistically significantly longer EFS. Patients in group A tended to have longer EFS, although the difference was not statistically significant ( Figure 1) .
The Cox proportional hazards model was used to assess the association of treatment groups with EFS, while adjusting for effects of other prognostic factors. Factors considered in the Cox model were treatment group, disease stage, b 2 -microglobulin level, and type of preparative regimens. b 2 -Microglobulin level was treated as a categorical variable, 0 if p4 mg/l, 1 otherwise. Stage was combined into two levels, I þ II, and III. Results are summarized in Table 4 . Although P values for each of the factors were lower when analyzed with other factors than when analyzed individually, hazard ratios were consistent with individual results. When groups B and C were compared to group A, hazard ratios were almost identical and considerably greater than 1.0, again consistent with findings of somewhat shorter EFS in the B and C groups charted in Figure 1 . However, the broad 95% confidence intervals which include values below 1.0 indicate that this study cannot completely rule out the possibility that the treatment regimen given to group A is actually inferior to those given to groups B and C. There was evidence of higher risk of progression associated with advanced disease stage and high b 2 -microglobulin level.
Discussion
Initial treatment for patients with symptomatic multiple myeloma has usually consisted of induction chemotherapy with a combination of steroids and an alkylating agent an anthracycline or combinations thereof. 2, 3, 18 Consolidation therapy for patients whose disease is responsive or stable with HDC supported by ASCT, or NMS induction prior to ASCT in myeloma A Anagnostopoulos et al intensification with ASCT in refractory patients, should be considered standard treatment for patients with acceptable performance status after having received induction therapy. 2 The impact of the type and duration of induction therapy on the outcomes of ASCT in multiple myeloma is unknown.
The use of a NMS induction (high-dose steroids with or without other NMS agents) on the results of ASCT could potentially increase the number of patients eligible for autograft, by avoiding the toxicities of myelosuppressive therapies, on the other hand, transplant outcomes could be negatively affected if more patients underwent transplant without achieving remission criteria or had inferior quality stem cells collected.
In this retrospective study, data from all patients with multiple myeloma who underwent ASCT as part of their induction treatment were collected and the impacts of NMS and myelosuppressive initial treatments were analyzed with the hypothesis that NMS induction treatment would not compromise the results of ASCT. Weber et al and Rajkumar et al 9, 10 have already documented the feasibility of stem cell collection after NMS induction therapy with thalidomide and dexamethasone. The results of this analysis in a larger group of patients confirm that stem cell collections are feasible even without chemomobilization in most myeloma patients. Thus it is possible to have myeloma patients undergo stem cell transplantation without ever receiving prior myelosuppressive agents.
This retrospective analysis also demonstrated that the degree of stem cell contamination with MPCs as determined by flow-cytometry was not higher in the patients who received NMS induction. Although the clinical relevance of graft contamination with MPCs has not been clearly shown, this observation supports the hypothesis that the quality of the stem cell graft will not be affected by a NMS induction regimen. 19 In this retrospective study, event-free and overall survival rates were at least equal in the group of patients who received a NMS induction treatment. Not withstanding this conclusion must be viewed with caution. Although, multivariate analysis was performed to account for the imbalances among prognostic factors in the different groups, this statistical method cannot eliminate the inherent biases that are involved in deciding which patients received a NMS induction or not. This analysis was also limited by the lack of prognostic factor information on all patients (ie cytogenetics and chromosome 13 abnormalities), nor were data available to analyze the impact of maintenance therapies. However, only well-designed prospective trials could account for these issues.
The recent publications of the efficacy of thalidomidedexamethasone combinations as induction therapy for myeloma provides an effective alternative to conventional myelosuppressive induction regimens. 9, 10 However, only well-designed prospective randomized trials looking at the impact of NMS induction therapies will provide a definite answer regarding the impact of different induction regimens on transplant outcome and assist myeloma patients and physicians in optimizing therapy prior to ASCT. Considering all the potential advantages of NMS induction together with the theoretical disadvantages these studies are urgently needed. The data in this analysis support the safety and efficacy of a NMS induction therapy for patients with myeloma for whom treatment with HDC and ASCT is intended and should provide an impetus for the development and implementation of those aforementioned studies. 
